What happened
Medy-Tox filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$48.5M (+11.4% year on year), operating profit of US$3.36M (−24.6% year on year) and net income of US$2.21M (−61.7% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$48.5M |
|---|---|
| Revenue vs a year earlier | +11.4% |
| Operating profit | US$3.36M |
| Net income | US$2.21M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-08-10, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260810900511 → open original filing |
Source: DART. Information only, not investment advice.